5:53 PM
 | 
Oct 29, 2013
 |  BC Extra  |  Clinical News

Lantheus reports Phase III data for imaging agent

Lantheus Medical Imaging Inc. (North Billerica, Mass.) reported data on Tuesday from a Phase III trial evaluating PET myocardial perfusion imaging (MPI) with the company's flurpiridaz F 18 injection to diagnose coronary artery disease (CAD) in 740 patients...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >